Everest Medicines Limited (HKG:1952)
Hong Kong
· Delayed Price · Currency is HKD 35.34
-0.32 (-0.90%)
Apr 29, 2026, 4:08 PM HKT
Everest Medicines Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 1,707 | 706.68 | 125.93 | 12.79 | 0.05 | Upgrade
|
| Revenue Growth (YoY) | 141.51% | 461.16% | 884.46% | 23588.89% | - | Upgrade
|
| Cost of Revenue | 524.82 | 181.8 | 34.41 | 4.65 | 0.02 | Upgrade
|
| Gross Profit | 1,182 | 524.88 | 91.52 | 8.15 | 0.03 | Upgrade
|
| Selling, General & Admin | 1,057 | 758.15 | 396.57 | 603.23 | 440.83 | Upgrade
|
| Research & Development | 511.04 | 528.04 | 540.05 | 809.74 | 613.43 | Upgrade
|
| Other Operating Expenses | -42.35 | 18.91 | 6.16 | -0.12 | -4.96 | Upgrade
|
| Operating Expenses | 1,526 | 1,305 | 942.78 | 1,413 | 1,049 | Upgrade
|
| Operating Income | -343.89 | -780.21 | -851.27 | -1,405 | -1,049 | Upgrade
|
| Interest Expense | -23.27 | -22.19 | -23.06 | -5.59 | -4.81 | Upgrade
|
| Interest & Investment Income | 116.01 | 95.21 | 107.67 | 38.48 | 28.88 | Upgrade
|
| Earnings From Equity Investments | -39.15 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 9.11 | 19.51 | -28.07 | -155.18 | 22.94 | Upgrade
|
| Other Non Operating Income (Expenses) | 26.2 | 2.65 | 2.82 | -1.61 | -6.46 | Upgrade
|
| EBT Excluding Unusual Items | -255 | -685.03 | -791.91 | -1,529 | -1,009 | Upgrade
|
| Gain (Loss) on Sale of Investments | -13.47 | -0.01 | 0.85 | -21.75 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.03 | - | -1.43 | 1,320 | - | Upgrade
|
| Asset Writedown | -333.23 | -356.34 | -51.97 | -16.49 | - | Upgrade
|
| Other Unusual Items | 3.37 | - | - | - | - | Upgrade
|
| Pretax Income | -598.36 | -1,041 | -844.46 | -247.28 | -1,009 | Upgrade
|
| Income Tax Expense | -300.6 | - | - | 0.01 | - | Upgrade
|
| Net Income | -297.77 | -1,041 | -844.46 | -247.28 | -1,009 | Upgrade
|
| Net Income to Common | -297.77 | -1,041 | -844.46 | -247.28 | -1,009 | Upgrade
|
| Shares Outstanding (Basic) | 336 | 321 | 313 | 298 | 293 | Upgrade
|
| Shares Outstanding (Diluted) | 336 | 321 | 313 | 298 | 293 | Upgrade
|
| Shares Change (YoY) | 4.84% | 2.51% | 5.18% | 1.49% | 243.61% | Upgrade
|
| EPS (Basic) | -0.89 | -3.24 | -2.70 | -0.83 | -3.44 | Upgrade
|
| EPS (Diluted) | -0.89 | -3.24 | -2.70 | -0.83 | -3.44 | Upgrade
|
| Free Cash Flow | -156.57 | -744.92 | -886.53 | -1,512 | -839.89 | Upgrade
|
| Free Cash Flow Per Share | -0.47 | -2.32 | -2.83 | -5.08 | -2.86 | Upgrade
|
| Gross Margin | 69.25% | 74.27% | 72.67% | 63.69% | 57.41% | Upgrade
|
| Operating Margin | -20.15% | -110.41% | -675.97% | -10981.12% | -1943096.30% | Upgrade
|
| Profit Margin | -17.45% | -147.36% | -670.57% | -1933.11% | -1867998.15% | Upgrade
|
| Free Cash Flow Margin | -9.17% | -105.41% | -703.97% | -11817.36% | -1555344.44% | Upgrade
|
| EBITDA | -211.18 | -670.04 | -795.72 | -1,391 | -1,043 | Upgrade
|
| EBITDA Margin | -12.37% | -94.82% | - | - | - | Upgrade
|
| D&A For EBITDA | 132.71 | 110.17 | 55.55 | 13.81 | 6.21 | Upgrade
|
| EBIT | -343.89 | -780.21 | -851.27 | -1,405 | -1,049 | Upgrade
|
| EBIT Margin | -20.15% | -110.41% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.